Company Overview - Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on cardiovascular and pulmonary diseases with high unmet medical need [4] - The company owns global rights to develop and commercialize levosimendan and may resume developing a unique oral formulation of imatinib [4] - Tenax Therapeutics' common stock is listed on The Nasdaq Stock Market under the symbol "TENX" [4] Upcoming Events - The company will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 5-6, 2025, in New York, NY [1] - Chris Giordano, President & CEO, will present on February 5, 2025, at 3:00 pm ET [2] - Management will also engage in one-on-one investor meetings during the conference [2] Investor Relations - A live and archived webcast of the presentation will be available on the company's investor relations webpage [3] - For one-on-one meeting requests, investors are encouraged to contact their Guggenheim representative [2]
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference